Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Automated Microbial Diagnostics

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2024

Same author

Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency.

Nature chemistry·2024

Same author

Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.

Scientific reports·2023

Same author

The Contribution of Liver Sinusoidal Endothelial Cells to Clearance of Therapeutic Antibody.

Frontiers in physiology·2022

Same author

Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action.

mAbs·2020

Same author

Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation.

Proceedings of the National Academy of Sciences of the United States of America·2020

Search research articles

Related Experiment Video

Updated: May 5, 2026

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Evolution of biologics screening technologies.

Peter Cariuk¹, Matthew J Gardener, Tristan J Vaughan

¹MedImmune Ltd, Milstein Building, Granta Park, Cambridge CB21 6GH, UK. CariukP@MedImmune.com.

Pharmaceuticals (Basel, Switzerland)

|November 27, 2013

Summary

This summary is machine-generated.

Antibody drug discovery screening has advanced from small molecule methods to specialized biologics technologies. This evolution enhances efficiency and accelerates the development of new antibody therapeutics.

More Related Videos

Procedure for Adaptive Laboratory Evolution of Microorganisms Using a Chemostat

Procedure for Adaptive Laboratory Evolution of Microorganisms Using a Chemostat

Published on: September 20, 2016

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Related Experiment Videos

Last Updated: May 5, 2026

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Procedure for Adaptive Laboratory Evolution of Microorganisms Using a Chemostat

Procedure for Adaptive Laboratory Evolution of Microorganisms Using a Chemostat

Published on: September 20, 2016

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

Area of Science:

Biopharmaceutical research and development
Drug discovery and development
Molecular biology and immunology

Background:

Early biologics screening relied on adapted small molecule discovery techniques.
Significant advancements in antibody drug discovery over the past two decades.
Growing demand for specialized large molecule screening technologies.

Purpose of the Study:

To review the historical evolution of screening and automation technologies in antibody discovery.
To highlight the benefits and impact of technological advancements in biologics screening.
To provide insights into current trends and future directions in antibody drug development.

Main Methods:

Review of historical screening processes and technologies used in biologics discovery.
Analysis of the adoption and modification of small molecule screening methods.
Examination of emerging technologies specifically developed for large molecule screening.

Main Results:

Demonstration of a significant shift from general screening to specialized antibody discovery platforms.
Identification of key technological innovations driving progress in biologics screening.
Quantification of benefits, including increased efficiency and earlier integration of advanced technologies.

Conclusions:

The field of antibody drug discovery has matured, necessitating dedicated and advanced screening solutions.
Investment in novel screening and automation technologies is crucial for continued progress.
Future developments will likely focus on further refining specialized technologies for biologics.